INC Research Expands Alliance Partnership Executive Team With New VP in Europe
News Nov 25, 2010
"We have experienced a very positive response to our alliance partnership program from sponsors of every type and size because of the economic advantages and focus on mutual goals and alignment," said Alistair Macdonald, executive vice president, Strategic Development at INC Research. "Manfred has the right scientific and strategic background to create alliance models that fit the unique requirements represented across the breadth of our current and prospective customer base. We believe clinical delivery alliances are the natural evolution in our industry and we are dedicated on being drivers of that innovation."
Dr. Weiler has a solid track record in life sciences with experience in building market-leading organizations. Prior to INC Research, he held management positions with SGS Group Management where he led its global CRO Business Development department with teams in Europe, US and Asia. At QIAGEN, he was responsible for the strategy, marketing, and future product developments of a joint venture of QIAGEN GmbH and Becton Dickinson, Inc., Franklin Lakes, USA. Dr. Weiler earned his Ph.D. degree in Biochemistry at the University of Bonn.
INC Research's clinical delivery alliance structures can include complete management of a compound or therapeutic area; management of a specific function or set of critical processes; sharing in the risk and reward of a compound's performance; or acting as the sole source development partner for a customer. The company's proven experience with process-driven clinical research methods and its popular metrics-based Trusted Process(R) provides the foundation for successful strategic alliances.
The cholesterol-lowering drugs called statins have demonstrated substantial benefits in reducing the risk of heart attacks and strokes caused by blood clots (ischemic strokes) in at-risk patients. Since statins are associated with a low risk of side effects, the benefits of taking them outweigh the risks, according to a scientific statement from the American Heart Association that reviewed multiple studies evaluating the safety and potential side effects of these drugs.READ MORE
18th International Conference on Pharmaceutics & Novel Drug Delivery Systems
May 27 - May 28, 2019
Global Experts Meeting on Frontiers in Biosimilars and Biologics Congress
Oct 24 - Oct 26, 2019